l 365031 has been researched along with ro 5-3438 in 1 studies
| Studies (l 365031) | Trials (l 365031) | Recent Studies (post-2010) (l 365031) | Studies (ro 5-3438) | Trials (ro 5-3438) | Recent Studies (post-2010) (ro 5-3438) |
|---|---|---|---|---|---|
| 7 | 0 | 0 | 7 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, PS; Bock, MG; Chang, RS; DiPardo, RM; Evans, BE; Freidinger, RM; Lundell, GF; Rittle, KE; Veber, DF; Whitter, WL | 1 |
1 other study(ies) available for l 365031 and ro 5-3438
| Article | Year |
|---|---|
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
Topics: Administration, Oral; Animals; Benzodiazepines; Chemical Phenomena; Chemistry; Cholecystokinin; Drug Design; Mice; Receptors, Cholecystokinin; Receptors, GABA-A; Structure-Activity Relationship | 1988 |